Illumina, Inc. (NASDAQ:ILMN) Receives Average Rating of “Hold” from Brokerages

Shares of Illumina, Inc. (NASDAQ:ILMN) have been assigned an average recommendation of “Hold” from the twenty brokerages that are covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, twelve have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $127.1765.

Several equities analysts recently issued reports on ILMN shares. Weiss Ratings reiterated a “hold (c-)” rating on shares of Illumina in a research report on Monday, December 29th. Robert W. Baird set a $109.00 price objective on Illumina in a research report on Friday, October 31st. Zacks Research lowered Illumina from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 31st. Wall Street Zen upgraded Illumina from a “hold” rating to a “buy” rating in a research report on Saturday, January 17th. Finally, Stifel Nicolaus upped their price target on Illumina from $135.00 to $155.00 and gave the stock a “buy” rating in a research note on Tuesday, January 20th.

Illumina Stock Performance

NASDAQ:ILMN opened at $149.69 on Friday. The stock has a market cap of $22.87 billion, a P/E ratio of 33.56, a price-to-earnings-growth ratio of 2.48 and a beta of 1.41. The firm’s fifty day simple moving average is $137.67 and its 200 day simple moving average is $114.58. Illumina has a twelve month low of $68.70 and a twelve month high of $155.53. The company has a quick ratio of 1.12, a current ratio of 1.43 and a debt-to-equity ratio of 0.42.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, October 30th. The life sciences company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.16 by $0.18. Illumina had a net margin of 16.40% and a return on equity of 29.21%. The business had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same period in the prior year, the business earned $1.14 EPS. The company’s revenue for the quarter was up .4% on a year-over-year basis. As a group, research analysts predict that Illumina will post 4.51 EPS for the current year.

Insider Transactions at Illumina

In other Illumina news, Director Scott Gottlieb bought 500 shares of Illumina stock in a transaction dated Monday, November 3rd. The shares were purchased at an average cost of $122.13 per share, with a total value of $61,065.00. Following the transaction, the director directly owned 12,523 shares of the company’s stock, valued at $1,529,433.99. This represents a 4.16% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Scott M. Davies sold 323 shares of Illumina stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $136.09, for a total transaction of $43,957.07. Following the transaction, the insider directly owned 17,887 shares of the company’s stock, valued at approximately $2,434,241.83. This trade represents a 1.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 2.60% of the stock is owned by corporate insiders.

Institutional Trading of Illumina

A number of hedge funds have recently made changes to their positions in the stock. Board of the Pension Protection Fund bought a new position in Illumina during the 4th quarter valued at approximately $26,000. Creative Capital Management Investments LLC increased its holdings in shares of Illumina by 160.0% during the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after acquiring an additional 120 shares in the last quarter. TD Waterhouse Canada Inc. purchased a new position in shares of Illumina in the 4th quarter worth about $26,000. Parkside Financial Bank & Trust boosted its stake in Illumina by 65.7% in the 2nd quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock worth $28,000 after purchasing an additional 115 shares in the last quarter. Finally, Quent Capital LLC purchased a new stake in Illumina during the 3rd quarter valued at about $29,000. 89.42% of the stock is owned by institutional investors.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.